Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Merck Sharp & Dohme LLC
EMD Serono
AstraZeneca
Sanofi
Abramson Cancer Center at Penn Medicine
Wake Forest University Health Sciences
NRG Oncology
Checkpoint Therapeutics, Inc.
Novartis
Novartis
Sanofi
Samsung Bioepis Co., Ltd.
Radiation Therapy Oncology Group
Bristol-Myers Squibb
AstraZeneca
AstraZeneca
Spanish Lung Cancer Group
Sumitomo Pharma America, Inc.
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Bristol-Myers Squibb
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
On Target Laboratories, LLC
Innovent Biologics (Suzhou) Co. Ltd.
Bristol-Myers Squibb
Southern Illinois University
Bristol-Myers Squibb
Amgen
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Radiation Therapy Oncology Group
Stanford University
AstraZeneca
Eli Lilly and Company
Milton S. Hershey Medical Center
Takeda
The Canadian College of Naturopathic Medicine
RTOG Foundation, Inc.
Genentech, Inc.
Merck Sharp & Dohme LLC
Celgene
Alliance for Clinical Trials in Oncology
Eli Lilly and Company
Bristol-Myers Squibb
Incyte Corporation
SWOG Cancer Research Network